Jefferies Financial Group Analysts Reduce Earnings Estimates for Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Analysts at Jefferies Financial Group decreased their Q2 2019 earnings per share (EPS) estimates for Neurocrine Biosciences in a research report issued on Tuesday, July 9th. Jefferies Financial Group analyst B. Amin now forecasts that the company will earn $0.18 per share for the quarter, down from their previous estimate of $0.40. Jefferies Financial Group also issued estimates for Neurocrine Biosciences’ Q3 2019 earnings at $0.49 EPS.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Monday, April 29th. The company reported ($1.12) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by ($0.07). The business had revenue of $138.40 million during the quarter, compared to analyst estimates of $136.77 million. Neurocrine Biosciences had a negative return on equity of 9.14% and a negative net margin of 7.56%. The business’s quarterly revenue was up 94.7% on a year-over-year basis. During the same period last year, the business earned ($0.47) EPS.

Other analysts have also recently issued research reports about the company. Guggenheim assumed coverage on resTORbio in a research report on Tuesday, June 4th. They issued a “buy” rating and a $28.00 target price for the company. Barclays set a GBX 6,800 ($88.85) target price on AstraZeneca and gave the stock a “buy” rating in a research report on Friday, March 29th. Credit Suisse Group assumed coverage on Regeneron Pharmaceuticals in a research report on Monday, May 20th. They issued a “neutral” rating and a $336.00 target price for the company. Evercore ISI assumed coverage on Homology Medicines in a research report on Thursday, April 11th. They issued an “outperform” rating and a $29.00 target price for the company. Finally, ValuEngine raised ZTE CORP/ADR from a “hold” rating to a “buy” rating in a research report on Monday, April 15th. Six equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Neurocrine Biosciences presently has an average rating of “Buy” and an average price target of $102.16.

Shares of Neurocrine Biosciences stock opened at $85.70 on Friday. The firm has a market capitalization of $7.85 billion, a PE ratio of 389.55 and a beta of 1.34. The stock has a fifty day simple moving average of $83.64. The company has a current ratio of 8.79, a quick ratio of 8.61 and a debt-to-equity ratio of 0.96. Neurocrine Biosciences has a 12 month low of $64.72 and a 12 month high of $126.98.

Several large investors have recently made changes to their positions in NBIX. Acadian Asset Management LLC acquired a new stake in shares of Neurocrine Biosciences in the fourth quarter worth about $32,000. Evolution Wealth Advisors LLC bought a new position in shares of Neurocrine Biosciences in the second quarter worth about $40,000. Quadrant Capital Group LLC increased its stake in shares of Neurocrine Biosciences by 9,242.9% in the first quarter. Quadrant Capital Group LLC now owns 654 shares of the company’s stock worth $56,000 after purchasing an additional 647 shares during the period. Arbor Wealth Management LLC bought a new position in shares of Neurocrine Biosciences in the fourth quarter worth about $92,000. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC increased its stake in shares of Neurocrine Biosciences by 75.2% in the fourth quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,120 shares of the company’s stock worth $151,000 after purchasing an additional 910 shares during the period. 95.86% of the stock is owned by institutional investors.

In other Neurocrine Biosciences news, insider Haig P. Bozigian sold 66,667 shares of the business’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $80.13, for a total value of $5,342,026.71. Following the completion of the sale, the insider now owns 164,415 shares of the company’s stock, valued at $13,174,573.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Haig P. Bozigian sold 19,297 shares of the business’s stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $85.02, for a total value of $1,640,630.94. Following the completion of the sale, the insider now directly owns 161,273 shares of the company’s stock, valued at approximately $13,711,430.46. The disclosure for this sale can be found here. Insiders sold 169,320 shares of company stock valued at $13,632,265 in the last ninety days. Insiders own 4.30% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Featured Article: How to Invest in the Dividend Aristocrat Index

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.